Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Halozyme Therapeutics Inc

Healthcare US HALO

71.835USD
2.02(2.89%)

Last update at 2026-06-04T18:09:00Z

Day Range

70.3371.89
LowHigh

52 Week Range

47.5082.22
LowHigh

Fundamentals

  • Previous Close 69.82
  • Market Cap8104.83M
  • Volume921447
  • P/E Ratio26.72
  • Dividend Yield-%
  • EBITDA897.84M
  • Revenue TTM1396.61M
  • Revenue Per Share TTM11.65
  • Gross Profit TTM 1086.35M
  • Diluted EPS TTM2.56

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 466.88M 557.13M 348.33M 248.92M 248.52M
Minority interest - - - - -
Net income 316.89M 444.09M 281.59M 202.13M 402.71M
Selling general administrative 207.09M 154.34M 149.18M 143.53M 50.32M
Selling and marketing expenses - - - - -
Gross profit 1091.17M 855.91M 636.89M 520.81M 361.90M
Reconciled depreciation 88.05M 81.31M 84.86M 49.64M 3.00M
Ebit 816.29M 575.23M 367.09M 267.53M 272.90M
Ebitda 904.34M 656.54M 451.95M 310.68M 275.90M
Depreciation and amortization 88.05M 81.31M 84.86M 43.15M 3.00M
Non operating income net other - - - -1.66600M -19.85800M
Operating income 816.29M 551.48M 337.57M 267.53M 275.90M
Other operating expenses 580.32M 463.85M 491.68M 392.58M 167.41M
Interest expense 18.13M 18.09M 18.76M 16.95M 7.53M
Tax provision 149.99M 113.04M 66.73M 46.79M -154.19200M
Interest income - - - - -
Net interest income -18.12600M -18.09500M -18.76200M -16.94700M -7.52600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 149.99M 113.04M 66.73M 46.79M -154.19200M
Total revenue 1396.61M 1015.32M 829.25M 660.12M 443.31M
Total operating expenses 274.88M 304.43M 299.32M 253.28M 86.00M
Cost of revenue 305.44M 159.42M 192.36M 139.30M 81.41M
Total other income expense net -349.41800M 5.66M 10.76M -18.61300M -27.38400M
Discontinued operations - - - - -
Net income from continuing ops 316.89M 444.09M 281.59M 202.13M 402.71M
Net income applicable to common shares - - - 202.13M 402.71M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2525.32M 2063.48M 1733.27M 1841.51M 1104.43M
Intangible assets 981.47M 401.83M 472.88M 546.65M -
Earning assets - - - - -
Other current assets 64.64M 38.95M 48.61M 45.02M 40.48M
Total liab 2476.51M 1699.66M 1649.46M 1671.71M 907.48M
Total stockholder equity 48.81M 363.82M 83.81M 169.80M 196.95M
Deferred long term liab - - - - -
Other current liab 156.19M 128.85M 100.68M 96.52M 24.44M
Common stock 0.12M 0.12M 0.13M 0.14M 0.14M
Capital stock 0.12M 0.12M 0.13M 0.14M 0.14M
Retained earnings 54.79M 359.87M 90.55M 143.22M -58.91200M
Other liab - - - 17.73M 3.07M
Good will 580.36M 416.82M 416.82M 409.05M -
Other assets - - - 71.23M 169.35M
Cash 133.82M 115.85M 118.37M 234.19M 118.72M
Cash and equivalents - - - - -
Total current liabilities 177.09M 139.10M 112.49M 130.79M 117.15M
Current deferred revenue - - -32.19700M 3.25M 1.75M
Net debt -133.82000M 1389.95M 1380.88M 1271.90M 757.96M
Short term debt - - 32.20M 13.33M 89.42M
Short long term debt - - - 13.33M 89.42M
Short long term debt total - 1505.80M 1499.25M 1506.10M 876.67M
Other stockholder equity 12.00M - 2.41M 27.37M 256.35M
Property plant equipment - - - 75.57M 8.79M
Total current assets 825.21M 1085.34M 746.42M 739.01M 926.29M
Long term investments - - - - -
Net tangible assets - - - -783.65000M 196.95M
Short term investments 9.00M 480.22M 217.63M 128.60M 622.20M
Net receivables 441.27M 308.45M 234.21M 231.07M 90.97M
Long term debt 2142.63M 1505.80M 1499.25M 1492.77M 787.25M
Inventory 176.47M 141.86M 127.60M 100.12M 53.91M
Accounts payable 20.90M 10.25M 11.82M 17.69M 1.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -18.09200M 3.83M -9.27800M -0.92200M -0.62000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.14M 0.14M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 143.22M -58.91200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 56.15M 80.60M 17.82M 26.80M 13.91M
Deferred long term asset charges - - - - -
Non current assets total 1700.12M 978.14M 986.85M 1102.50M 178.14M
Capital lease obligations - - - - -
Long term debt total - - - 1492.77M 787.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 474.89M -262.72300M -96.90900M 490.92M -404.83200M
Change to liabilities - - - 24.54M 1.17M
Total cashflows from investing activities -545.81300M -262.72300M -96.90900M -487.00500M -406.28900M
Net borrowings 451.13M 0.00000M -13.48300M 617.44M 415.81M
Total cash from financing activities -85.17400M -218.86100M -407.98700M 362.37M 77.86M
Change to operating activities - - - -9.06400M -11.55500M
Net income 316.89M 444.09M 281.59M 202.13M 402.71M
Change in cash 20.57M -2.52000M -116.32500M 115.48M -28.98400M
Begin period cash flow 115.85M 118.37M 234.69M 119.22M 148.20M
End period cash flow 136.42M 115.85M 118.37M 234.69M 119.22M
Total cash from operating activities 651.56M 479.06M 388.57M 240.11M 299.44M
Issuance of capital stock - - - - -
Depreciation 88.05M 88.66M 84.86M 49.64M 3.00M
Other cashflows from investing activities -287.77100M -252.02700M - -973.11400M -
Dividends paid - - 13.48M - -12.53600M
Change to inventory 2.55M -67.38100M -26.88400M -17.48100M 7.37M
Change to account receivables -128.06300M -74.24500M -3.33900M -83.94100M 6.75M
Sale purchase of stock -342.37200M -250.00000M -402.38300M -200.00200M -350.05800M
Other cashflows from financing activities -85.17400M 31.14M 7.88M 995.78M 796.99M
Change to netincome - - - 67.02M -113.64700M
Capital expenditures 6.97M 10.70M 15.29M 4.81M 1.46M
Change receivables - - - -83.94100M 6.75M
Cash flows other operating - - - -10.73400M -13.80200M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 115.48M -28.98400M
Change in working capital -152.25600M -136.27000M -38.67100M -85.95100M 3.74M
Stock based compensation 51.56M 43.38M 36.62M 24.40M 20.82M
Other non cash items 346.68M 39.20M -10.33400M 9.89M 24.61M
Free cash flow 644.59M 468.37M 373.28M 235.30M 297.98M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HALO
Halozyme Therapeutics Inc		 2.02 2.89% 71.83 26.72 5.13 5.80 168.90 7.34 17.88
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics Inc

12390 El Camino Real, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. Pres, CEO & Director 1963
Dr. Michael J. LaBarre Ph.D. Chief Technical Officer 1964
Ms. Nicole LaBrosse CFO & Director 1983
Ms. Tram Bui VP of Investor Relations & Corp. Communications NA
Mr. Mark Snyder Esq. Gen. Counsel, Chief Compliance Officer & Corp. Sec. NA
Ms. Amy Marinne Fox Chief HR Officer NA
Dr. Steve Knowles MBBS Chief Medical Officer NA
Mr. Todd Butler Chief of Staff to the CEO, VP & Head of Project Management NA
Dr. Christopher Bryant Ph.D. Chief Manufacturing Officer & Head of Technical Operations 1961
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. President, CEO & Director 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.